Adlai Nortye (ANL) Debt to Equity (2022 - 2025)

Adlai Nortye (ANL) reported Debt to Equity of -$2.95 for Q4 2025, down 385.91% year-over-year from $1.03 in Q4 2024, and down 385.91% on a QoQ basis from $1.03 in Q4 2024.

Adlai Nortye (ANL) has 4 years of Debt to Equity data on file, last reported at -$2.95 in Q4 2025.

  • Quarterly Debt to Equity fell 385.91% year-over-year to -$2.95 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$2.95 (down 385.91% YoY) and the FY2025 annual result came in at -$2.95, down 385.91% from the prior year.
  • Debt to Equity fell to -$2.95 in Q4 2025 per ANL's latest filing, from $1.03 in the prior quarter.
  • Across five years, Debt to Equity topped out at $1.03 in Q4 2024 and bottomed at -$2.95 in Q4 2025.
  • The 4-year median for Debt to Equity is $0.4 (2023), against an average of -$0.16.
  • The widest annual swing landed in 2023, when Debt to Equity surged 2366.22%; it then plunged 385.91% in 2025.
  • Tracing ANL's Debt to Equity over 4 years: stood at -$0.02 in 2022, then surged by 2366.22% to $0.4 in 2023, then soared by 155.41% to $1.03 in 2024, then sank by 385.91% to -$2.95 in 2025.
  • Per Business Quant, the three latest ANL Debt to Equity figures stand at -$2.95 (Q4 2025), $1.03 (Q4 2024), and $0.73 (Q2 2024).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt/Equity (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn - -
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn - -
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn -
4 Nanobiotix 2,282.79 Bn 2,282.72 Bn - -
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn - -
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn -
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn 0.06
8 Evaxion A 65.44 Bn 65.42 Bn - -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn -
10 Adlai Nortye 23,840.00 -8.03 Mn - -2.95

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 -2.95
Dec 31, 2024 1.03
Jun 30, 2024 0.73
Dec 31, 2023 0.40
Dec 31, 2022 -0.02